More on LGND
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $305.47 |
|
|||
| Open | $305.47 | ||||
| 52 Wk High | $139.79 | ||||
| 52 Wk Low | $82.07 | ||||
| Day High | $305.47 | ||||
| Day Low | $305.47 | ||||
| P/E | 710.40 | ||||
| EPS | $0.43 | ||||
| Volume | 591 | ||||
- Citi resumes Ligand Pharma coverage with Buy rating, $387 target
- Ligand Pharma (LGND) PT Raised to $335 at Benchmark as XOMA Royalty Cash Acquisition Completed
- Ligand Pharma (LGND) PT Raised to $340 at RBC Capital
- Form 8-K LIGAND PHARMACEUTICALS For: Jul 14
- Ligand completes acquisition of XOMA Royalty at $39 per share
- Ligand completes $739M acquisition of XOMA Royalty
- Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
- XOMA Royalty Announces Closing of Its Acquisition by Ligand
- Ligand Pharma (LGND) PT Raised to $388 at BofA Securities
- Ligand Pharma (LGND) PT Raised to $332 at Stifel as Xoma Asset Acquisition Announced
Entities mentioned with LGND
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Roth Capital | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
